Daewoong Pharmaceutical has entered an exclusive licensing agreement with CS Pharmaceuticals (CSP) for Bersiporocin, a first-in-class PRS inhibitor, in the Greater China region for Idiopathic Pulmonary Fibrosis (IPF).

Under the deal, CSP will have exclusive rights for the development and marketing of Bersiporocin to treat IPF as well as other respiratory indications in the region, including mainland China, Macau, Hong Kong, and Taiwan.

As per the terms of the agreement, Daewoong will receive a total consideration of up to $336m, including upfront and development milestone payments of up to $76m, along with royalties on net sales.

Being developed by Daewoong, Bersiporocin has already received FastTrack Designation and Orphan Drug Designation from the US Food and Drug Administration (FDA) to treat IPF.

Last year, the company commenced a multi-regional Phase II clinical trial of Bersiporocin for IPF treatment, with results expected in the first half of next year.

The Korea Drug Development Fund is supporting the trial by providing funds.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

CSP CEO Darren Mercer said: “Securing the Chinese commercial rights to Bersiporocin with the initial focus in IPF marks another milestone for CSP, as we continue to expand our portfolio of innovative products in China.

“IPF is a priority rare disease in China, which marks a huge unmet need. It is currently estimated that nearly 50% of IPF patients in China will die within two to three years after diagnosis.

“Completing this transaction further strengthens our rare disease portfolio as we continue to focus on bringing innovative rare disease and ophthalmology medicines to Chinese patients, to address the significant unmet medical needs in this rapidly growing market.”